#70 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
I don’t see an article provided for me to reference. To write an authentic clinical quote from Dr. Benjamin Caplan responding to a specific article, I would need you to share the article text or provide more details about its content. Could you please provide the article you’d like me to have Dr. Caplan respond to?
The U.S. Drug Enforcement Administration’s placement of ethylphenidate, a metabolite of methylphenidate (Ritalin), into Schedule I reflects growing regulatory attention to novel psychoactive substances and designer drugs that circumvent existing controlled substance frameworks. Ethylphenidate has emerged in illicit drug markets as a chemical analog with stimulant properties similar to prescription ADHD medications, creating a public health concern distinct from legitimate clinical use of FDA-approved agents. Healthcare providers should remain aware that patients may encounter or misuse these unregulated compounds, which lack quality control, safety data, and predictable pharmacokinetics compared to approved medications. The regulatory action underscores the importance of careful substance use history-taking and patient education about the risks of obtaining stimulants outside legitimate prescribing channels, particularly among adolescents and young adults. Clinicians managing ADHD or substance use disorders should incorporate awareness of these emerging drugs
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: